505 related articles for article (PubMed ID: 26651341)
1. Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.
Head E; Lott IT; Wilcock DM; Lemere CA
Curr Alzheimer Res; 2016; 13(1):18-29. PubMed ID: 26651341
[TBL] [Abstract][Full Text] [Related]
2. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
Asai M; Kawakubo T; Mori R; Iwata N
Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290
[TBL] [Abstract][Full Text] [Related]
3. HNE-modified proteins in Down syndrome: Involvement in development of Alzheimer disease neuropathology.
Barone E; Head E; Butterfield DA; Perluigi M
Free Radic Biol Med; 2017 Oct; 111():262-269. PubMed ID: 27838436
[TBL] [Abstract][Full Text] [Related]
4. Genetics of β-Amyloid Precursor Protein in Alzheimer's Disease.
Tcw J; Goate AM
Cold Spring Harb Perspect Med; 2017 Jun; 7(6):. PubMed ID: 28003277
[TBL] [Abstract][Full Text] [Related]
5. Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome.
Moncaster JA; Pineda R; Moir RD; Lu S; Burton MA; Ghosh JG; Ericsson M; Soscia SJ; Mocofanescu A; Folkerth RD; Robb RM; Kuszak JR; Clark JI; Tanzi RE; Hunter DG; Goldstein LE
PLoS One; 2010 May; 5(5):e10659. PubMed ID: 20502642
[TBL] [Abstract][Full Text] [Related]
6. Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer's disease.
Streit WJ; Braak H; Xue QS; Bechmann I
Acta Neuropathol; 2009 Oct; 118(4):475-85. PubMed ID: 19513731
[TBL] [Abstract][Full Text] [Related]
7. Untangle the mystery behind DS-associated AD - Is APP the main protagonist?
Elangovan A; Babu HWS; Iyer M; Gopalakrishnan AV; Vellingiri B
Ageing Res Rev; 2023 Jun; 87():101930. PubMed ID: 37031726
[TBL] [Abstract][Full Text] [Related]
8. Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.
Chen XQ; Salehi A; Pearn ML; Overk C; Nguyen PD; Kleschevnikov AM; Maccecchini M; Mobley WC
Alzheimers Dement; 2021 Feb; 17(2):271-292. PubMed ID: 32975365
[TBL] [Abstract][Full Text] [Related]
9. Evidence against the overexpression of APP in Down syndrome.
Argellati F; Massone S; d'Abramo C; Marinari UM; Pronzato MA; Domenicotti C; Ricciarelli R
IUBMB Life; 2006 Feb; 58(2):103-6. PubMed ID: 16608822
[TBL] [Abstract][Full Text] [Related]
10. Aβ-induced acceleration of Alzheimer-related τ-pathology spreading and its association with prion protein.
Gomes LA; Hipp SA; Rijal Upadhaya A; Balakrishnan K; Ospitalieri S; Koper MJ; Largo-Barrientos P; Uytterhoeven V; Reichwald J; Rabe S; Vandenberghe R; von Arnim CAF; Tousseyn T; Feederle R; Giudici C; Willem M; Staufenbiel M; Thal DR
Acta Neuropathol; 2019 Dec; 138(6):913-941. PubMed ID: 31414210
[TBL] [Abstract][Full Text] [Related]
11. Anti-IL17 treatment ameliorates Down syndrome phenotypes in mice.
Rueda N; Vidal V; García-Cerro S; Narcís JO; Llorens-Martín M; Corrales A; Lantigua S; Iglesias M; Merino J; Merino R; Martínez-Cué C
Brain Behav Immun; 2018 Oct; 73():235-251. PubMed ID: 29758264
[TBL] [Abstract][Full Text] [Related]
12. Characterization of monomeric and soluble aggregated Aβ in Down's syndrome and Alzheimer's disease brains.
Gkanatsiou E; Sahlin C; Portelius E; Johannesson M; Söderberg L; Fälting J; Basun H; Möller C; Odergren T; Zetterberg H; Blennow K; Lannfelt L; Brinkmalm G
Neurosci Lett; 2021 May; 754():135894. PubMed ID: 33848613
[TBL] [Abstract][Full Text] [Related]
13. mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia.
Di Domenico F; Tramutola A; Foppoli C; Head E; Perluigi M; Butterfield DA
Free Radic Biol Med; 2018 Jan; 114():94-101. PubMed ID: 28807816
[TBL] [Abstract][Full Text] [Related]
14. Possible compensatory events in adult Down syndrome brain prior to the development of Alzheimer disease neuropathology: targets for nonpharmacological intervention.
Head E; Lott IT; Patterson D; Doran E; Haier RJ
J Alzheimers Dis; 2007 Mar; 11(1):61-76. PubMed ID: 17361036
[TBL] [Abstract][Full Text] [Related]
15. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
16. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
[TBL] [Abstract][Full Text] [Related]
17. Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease.
Oddo S; Caccamo A; Kitazawa M; Tseng BP; LaFerla FM
Neurobiol Aging; 2003 Dec; 24(8):1063-70. PubMed ID: 14643377
[TBL] [Abstract][Full Text] [Related]
18. Genetic Mapping of APP and Amyloid-β Biology Modulation by Trisomy 21.
Mumford P; Tosh J; Anderle S; Gkanatsiou Wikberg E; Lau G; Noy S; Cleverley K; Saito T; Saido TC; Yu E; Brinkmalm G; Portelius E; Blennow K; Zetterberg H; Tybulewicz V; Fisher EMC; Wiseman FK
J Neurosci; 2022 Aug; 42(33):6453-6468. PubMed ID: 35835549
[TBL] [Abstract][Full Text] [Related]
19. Cerebrovascular contributions to aging and Alzheimer's disease in Down syndrome.
Wilcock DM; Schmitt FA; Head E
Biochim Biophys Acta; 2016 May; 1862(5):909-14. PubMed ID: 26593849
[TBL] [Abstract][Full Text] [Related]
20. Rodent Modeling of Alzheimer's Disease in Down Syndrome:
Farrell C; Mumford P; Wiseman FK
Front Neurosci; 2022; 16():909669. PubMed ID: 35747206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
